6,774 results match your criteria Onkologie [Journal]


Cancer patients' needs for virtues and physicians' characteristics in physician-patient communication: a survey among patient representatives.

Support Care Cancer 2018 Dec 6. Epub 2018 Dec 6.

Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.

Background: Data on patients' needs with respect to physicians' ethical behavior and virtues are important but not available in most cases.

Patients And Methods: In an iterative process together with patients' representatives, we developed a standardized questionnaire which was distributed to the representatives of the Women's Self-Help after Cancer in Germany. We started with the classical ethical virtues and clustered them to characteristics. Read More

View Article
December 2018

Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.

Biomed Res Int 2018 24;2018:1374821. Epub 2018 Jun 24.

Universitäts-Frauenklinik Heidelberg, Germany.

Uterine fibroids are the most frequent benign tumours in women of child-bearing age. Their symptoms are diverse and the quality of life of the women affected can be significantly impaired. While treatment to date has been primarily by means of surgical intervention, selective progesterone receptor modulators (SPRMs) open up new medication-based treatment options. Read More

View Article
June 2018
1 Read

[Use of Negative Pressure Wound Therapy with Instillation and Dwell Time for Wound Treatment - Results of an Expert Consensus Conference].

Zentralbl Chir 2018 Dec 11;143(6):609-616. Epub 2018 Dec 11.

Unfallchirurgie, Bundeswehrkrankenhaus Berlin, Deutschland.

Rinsing wounds with wound cleansing solutions has long been a recognised cornerstone in wound management as a means of removing cell debris and surface pathogens in wound exudates. In combination with surgical debridement and topical negative pressure wound therapy (NPWT), this can facilitate the intended progression from the inflammatory to the proliferative phase of wound healing. Procedures of topical negative pressure wound therapy with instillation and a defined exposure/dwell-time of topical solutions under cyclic compression and decompression with foam dressings (NPWTi-d) can remove cellular remnants and debris that may inhibit the healing process. Read More

View Article
December 2018
2 Reads

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Eur J Cancer 2018 Dec 6;107:37-45. Epub 2018 Dec 6.

Dept. of Urology, Rechts der Isar Medical Center, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany; AUO Study Group, Germany. Electronic address:

Purpose: This trial compared the sequential therapy with the multikinase inhibitor sorafenib (So) followed by pazopanib (Pa) or vice versa in advanced/metastatic renal cell carcinoma (mRCC) patients.

Methods: This multicenter, randomized phase 3 study assessed the sequential use of So-Pa versus Pa-So in patients with mRCC without prior systemic therapy. Pts were randomized to So 2 × 400 mg/day followed by Pa 1 × 800 mg/day in case of progression or intolerable toxicity or vice versa. Read More

View Article
December 2018

[The Rezūm system in the treatment of male lower urinary tract symptoms (LUTSs) due to benign prostatic obstruction (BPO)].

Aktuelle Urol 2018 Dec 6;49(6):519-524. Epub 2018 Dec 6.

Spital Thurgau AG, Urologie, Frauenfeld.

The classical algorithm of the management of male lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH) includes a surgical approach in case pharmacological therapy has failed. Emerging minimally-invasive treatments (MITs) offer potential for rapid symptomatic relief, reducing the morbidity of invasive BPH surgery. Convective interstitial radiofrequency water vapour thermal ablation of the prostate with the Rezūm system is a novel MIT for the treatment of bothersome moderate-to-severe lower urinary tract symptoms associated with BPH. Read More

View Article
December 2018
10 Reads

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Department of Haematology, Oncology, Haemostaseology, and Pneumology, University Hospital, Münster, Germany.

To further improve outcome in young high-risk patients with diffuse large B-cell lymphoma (DLBCL) the number of rituximab (R) infusions was doubled in combination with standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone) chemotherapy. Seventy-seven patients (aged 18-60 years) with an age-adjusted International Prognostic Index of 2-3 received 12 × R (375 mg/m ) on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85 and 99 together with eight cycles of CHOEP-14. Results were retrospectively compared to those of patients receiving 6 × R and 8 × CHOEP-14 in the standard arm of the randomized R-MegaCHOEP trial. Read More

View Article
December 2018
4 Reads

[Cheek-midface lift for revision following failed excessive lower eyelid blepharoplasty].

Ophthalmologe 2018 Dec 5. Epub 2018 Dec 5.

Zentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Iatrogenic ectropion with sagging of the lower eyelid after failed excessive lower eyelid blepharoplasty is a severe complication in aesthetic surgery. Traditionally, free skin grafting is the method of choice for correction. This overview presents the cheek-midface lift as a useful and powerful method for the correction of ectropion following excessive lower eyelid blepharoplasty. Read More

View Article
December 2018
1 Read

Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging.

Cells 2018 Nov 29;7(12). Epub 2018 Nov 29.

Institute of Biochemistry and Biophysics, Center for Molecular Biomedicine (CMB), Friedrich Schiller University Jena, Hans-Knöll-Str. 2, 07745 Jena, Germany.

In complex organisms, stem cells are key for tissue maintenance and regeneration. Adult stem cells replenish continuously dividing tissues of the epithelial and connective types, whereas in non-growing muscle and nervous tissues, they are mainly activated upon injury or stress. In addition to replacing deteriorated cells, adult stem cells have to prevent their exhaustion by self-renewal. Read More

View Article
November 2018

[Pressure study of two miniaturised amplatz sheaths of 9.5 F and 12 F outer diameter for minimal invasive percutaneous nephrolithotomy (MIP): An ex vivo organ model measurement].

Aktuelle Urol 2018 Dec 5. Epub 2018 Dec 5.

Landeskrankenhaus Hall, Klinik für Urologie und Andrologie, Hall, Österreich.

Over the last decade, several devices for percutaneous nephrolithotomy with smaller diameters have been introduced in order to reduce renal trauma. Recent studies have found comparable stone free rates but also exhibit the same rate of postoperative fever and septicaemia. One possible cause is the influence of irrigation fluid during stone treatment procedures. Read More

View Article
December 2018
2 Reads

[Preparedness to provide care in relation to the satisfaction with hospital discharge planning and level of knowledge of relatives to elderly patients].

Pflege 2018 Dec 5:1-12. Epub 2018 Dec 5.

4 Nursing Science & Care GmbH, Winterthur.

Preparedness to provide care in relation to the satisfaction with hospital discharge planning and level of knowledge of relatives to elderly patients Abstract.

Background: Relatives are a great resource for older people who are discharged after hospitalization. Studies have so far shown very little about the readiness of relatives to aid in caregiving. Read More

View Article
December 2018

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med 2018 Dec 5. Epub 2018 Dec 5.

From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

Background: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy.

Methods: We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Read More

View Article
December 2018
13 Reads

[New treatment options for iridociliary tumors].

Ophthalmologe 2018 Dec 4. Epub 2018 Dec 4.

Zentrum für Augenheilkunde, Universität zu Köln, Kerpener Str. 62, 50924, Köln, Deutschland.

Background: Benign iridal tumors rarely necessitate a therapeutic intervention. In contrast, malignant tumors of the iris can threaten the patient's life and eyesight and require early treatment to prevent the development of metastases.

Objective: Presentation of current treatment options for iridal tumors with special emphasis on iridal melanoma. Read More

View Article
December 2018
2 Reads

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.

J Bone Oncol 2019 Feb 2;14:010-10. Epub 2018 Oct 2.

Department of Oncology, Bethanien Hospital, Frankfurt am Main, Germany.

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study.

Methods: The 4EVER trial investigated everolimus in combination with exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. Read More

View Article
February 2019
2 Reads

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Munich.

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. Read More

View Article
December 2018
1 Read

Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer.

Geburtshilfe Frauenheilkd 2018 Nov 26;78(11):1119-1128. Epub 2018 Nov 26.

OncoConsult Hamburg GmbH, Hamburg, Germany.

New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Read More

View Article
November 2018

Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.

Geburtshilfe Frauenheilkd 2018 Nov 26;78(11):1110-1118. Epub 2018 Nov 26.

Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.

In primary early breast cancer, the aim of treatment planning is to obtain an increasingly better understanding of the disease. The identification of patients with an excellent prognosis could help this group avoid unnecessary treatments. Furthermore, the planning of treatment is becoming increasingly patient-focussed. Read More

View Article
November 2018
4 Reads

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Eur J Cancer 2018 Nov 26;106:115-125. Epub 2018 Nov 26.

Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.

Purpose: Increased baseline carcinoembryonic antigen (CEA) serum level is associated with inferior overall survival (OS) in metastatic colorectal cancer (mCRC). However, limited data exist on its predictive relevance for targeted therapies. Therefore, we analysed its relevance in FIRE-3, a randomised phase III study. Read More

View Article
November 2018
6 Reads

Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study.

Eur Heart J 2018 Nov 28. Epub 2018 Nov 28.

Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, Leipzig, Germany.

Aims: It is unknown whether different training modalities exert differential cellular effects. Telomeres and telomere-associated proteins play a major role in cellular aging with implications for global health. This prospective training study examines the effects of endurance training, interval training (IT), and resistance training (RT) on telomerase activity and telomere length (TL). Read More

View Article
November 2018

Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

Br J Cancer 2018 Dec 27;119(12):1445-1450. Epub 2018 Nov 27.

Department of Urology, University College London Hospital, London, UK.

Background: Active surveillance is recommended for insignificant prostate cancer (PCa). Tools exist to identify suitable candidates using clinical variables. We aimed to develop and validate a novel risk score (NRS) predicting which patients are harbouring insignificant PCa. Read More

View Article
December 2018

[S3 guideline breast cancer: update on early detection, and mammography screening].

Radiologe 2018 Nov 22. Epub 2018 Nov 22.

Radiologische Ambulanz Hamburg, Hamburg, Deutschland.

Based on the update of the S3-Guideline Early Detection, Diagnosis, Treatment and Follow-up Care of Breast Cancer (Version 4.0, December 2017, AWMF registry number 032-045OL, www.leitlinienprogramm-onkologie. Read More

View Article
November 2018
1 Read

[Evolving Epidemiology of Home Mechanical Ventilation: A Rapidly Growing Challenge for Patient Care].

Dtsch Med Wochenschr 2018 Nov 21. Epub 2018 Nov 21.

Lungenklinik Köln-Merheim, ARDS- und ECMO-Zentrum, Kliniken der Stadt Köln gGmbH, Köln, Universität Witten/Herdecke, Fakultät für Gesundheit/Department für Humanmedizin.

Background:  Home mechanical ventilation is dramatically evolving in Germany. Patients with non-invasive and invasive ventilation are increasingly treated at home. In-hospital treatment of these patients is also necessary either for control visits or the management of acute medical problems. Read More

View Article
November 2018
1 Read

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.

Int Immunopharmacol 2019 Jan 15;66:119-126. Epub 2018 Nov 15.

CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406, USA. Electronic address:

Purpose: Primary (PID) and secondary immune deficiencies (SID) represent diverse groups of diagnoses, yet both can be effectively treated with intravenous immunoglobulin (IVIG) replacement therapy. Guidelines for the use of IVIG in SID vary due to the paucity of data. The objective was to analyze available IVIG Privigen® (IgPro10, CSL Behring, Bern, Switzerland) data on Efficiency Index (EI) and pharmacokinetic (PK) parameters in patients with PID and SID. Read More

View Article
January 2019
4 Reads

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Lancet Oncol 2018 Dec 12;19(12):1668-1679. Epub 2018 Nov 12.

Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany.

Background: Monitoring of measurable residual disease (MRD) in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a morphological complete remission can predict haematological relapse. In this prospective study, we aimed to determine whether MRD-guided pre-emptive treatment with azacitidine could prevent relapse in these patients.

Methods: The relapse prevention with azacitidine (RELAZA2) study is an open-label, multicentre, phase 2 trial done at nine university health centres in Germany. Read More

View Article
December 2018
12 Reads

Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.

Lung Cancer 2018 Nov 25;125:164-173. Epub 2018 Sep 25.

Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany.

Introduction: Local ablative treatment (LAT) improves outcome in lung cancer with oligometastatic disease (OMD) and potentially leads to long term survival. The aim of this retrospective study was to evaluate and quantify the additional benefit of LAT in synchronous OMD and to further identify prognostic factors for survival.

Patients And Methods: A propensity score-matched pairs analysis was performed on a set of patient and disease variables in 180 patients, treated for synchronous single organ OMD including non small-cell and neuroendocrine lung cancer with ≤4 metastases between 2000 and 2016 in 3 lung cancer centers in Berlin, Germany. Read More

View Article
November 2018
2 Reads

Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study.

PLoS One 2018 14;13(11):e0206450. Epub 2018 Nov 14.

Department of Radiology, Charité, Berlin, Germany.

Non-alcoholic fatty liver disease (NAFLD) was shown to also occur in lean and underweight patients. So far, the prevalence of NAFLD in underweight individuals with and without inflammatory bowel disease (IBD) is insufficiently enlightened. In this cross-sectional age, gender and disease-matched case-control study, underweight patients (BMI<18. Read More

View Article
November 2018
6 Reads

Contrast-Enhanced Sonography in Patients with Hyposplenia: A Retrospective Analysis in Forty-Three Patients.

Digestion 2018 Nov 13:1-6. Epub 2018 Nov 13.

Interdisziplinäre Ultraschallzentrum, Universitätsklinikum Gießen und Marburg, Philipps Universität Marburg, Marburg, Germany.

Purpose: In contrast to splenomegaly, the clinical value of a small spleen (hyposplenia) is unclear. Contrast-enhanced ultrasound (CEUS) has not been investigated systematically in hyposplenia.

Methods: Between February 2005 and January 2017, 43 patients with hyposplenia (< 7 × 3 cm) were examined by B-mode ultrasound (US) and CEUS. Read More

View Article
November 2018
1 Read

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

J Allergy Clin Immunol Pract 2018 Nov 8. Epub 2018 Nov 8.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria.

Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Read More

View Article
November 2018
19 Reads

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease.

Bone Marrow Transplant 2018 Nov 9. Epub 2018 Nov 9.

HELIOS Klinikum Berlin-Buch, Berlin, Germany.

Salvage chemotherapy induces disease remissions in patients with relapsed or refractory (r/r) T-cell lymphomas, but fails to provide lasting tumor control. We analyzed the outcome after peripheral blood stem and bone marrow transplantation (PBSCT, n = 80; BMT, n = 4) from matched related (MRD, n = 22) or matched and unmatched unrelated donors (MUD and MMD, n = 53 and n = 9, respectively) following conditioning with fludarabine, busulfan, and cyclophosphamide (FBC) for 84 consecutive patients with r/r T-cell malignancies. At start of conditioning LDH was elevated in 50% of cases, and residual tumor (PD, SD, PR) was detectable in 84% of patients. Read More

View Article
November 2018
5 Reads

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

Oncotarget 2018 Oct 5;9(78):34794-34809. Epub 2018 Oct 5.

IndivuTest GmbH, Hamburg, Germany.

A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. Read More

View Article
October 2018
3 Reads

Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how.

Oncotarget 2018 Oct 5;9(78):34642-34643. Epub 2018 Oct 5.

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article
October 2018

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

Pneumologie 2018 Nov 8;72(11):774-781. Epub 2018 Nov 8.

Klinik I für Innere Medizin, Centrum für Integrierte Onkologie, Uniklinik Köln, Köln.

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) are widely used in non-small cell lung cancer patients harboring activating EGFR mutations. However, resistance mechanisms, particularly the T790 M mutation, hamper longer-term therapeutic success of first and second generation EGFR-TKIs. To address this unmet medical need, EGFR-TKIs of the third generation are under clinical development. Read More

View Article
November 2018
3 Reads

[TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes].

Pathologe 2018 Nov 8. Epub 2018 Nov 8.

Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Deutschland.

Background: The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy.

Objectives: Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study. Read More

View Article
November 2018
4 Reads

Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Nat Commun 2018 11 7;9(1):4655. Epub 2018 Nov 7.

Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR-negative but EGFR-positive subclones and osimertinib resistance. We demonstrate that EGFR limits the activity of third-generation EGFR inhibitors both in vitro and in vivo. Read More

View Article
November 2018
10 Reads

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Blood 2018 Nov 7. Epub 2018 Nov 7.

European Myelodysplastic Syndromes Cooperative Group, Germany.

The heterogeneity of myelodysplastic syndromes (MDS) has made evaluating patient response to treatment challenging. In 2006, an International Working Group (IWG) proposed a revision to previously published standardized response criteria (IWG 2000) for uniformly evaluating clinical responses in MDS. These IWG 2006 criteria have been used prospectively in many clinical trials in MDS, but proved challenging in several of them, especially for the evaluation of erythroid response. Read More

View Article
November 2018
2 Reads

[Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers].

HNO 2018 Dec;66(12):880-887

Klinik für Hals-Nasen-Ohrenheilkunde und Kopf-Hals-Chirurgie, Kopf-Hals-Tumorzentrum, Universitätsklinikum Ulm, Frauensteige 12, 87070, Ulm, Deutschland.

Background: Immunotherapeutic strategies are becoming increasingly more important for head and neck cancer and numerous clinical trials were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2018.

Objective: In this review the most interesting clinical trials and trial results for immunotherapy of head and neck cancer are summarized.

Material And Methods: All abstracts and presentations on immunotherapy of head and neck cancer at the annual meeting of the ASCO 2018 were screened to select the most interesting trials for a more detailed analysis. Read More

View Article
December 2018
2 Reads

[Long-Term Follow-Up in Childhood Cancer Survivors - Position paper 2018 of the working group "long-term follow-up" of the Society of Pediatric Oncology and Hematology (GPOH) on long-term surveillance, long-term follow-up and late effect evaluation in pediatric oncology patients].

Klin Padiatr 2018 Oct 6;230(6):291-298. Epub 2018 Nov 6.

Abteilung für Pädiatrische Hämatologie und Onkologie, Zentrum fur Kinderheilkunde der Universitat Bonn, Bonn.

Nowadays, childhood cancer patients survive much more often than they did 40 years ago. Therefore, the cure rates rise over 80%. Approximately 33,000 cured childhood cancer patients are documented by the German Childhood Cancer Registry (GCCR) for long-term follow-up in Germany. Read More

View Article
October 2018
6 Reads

T-cell-secreted TNF-alpha induces emergency myelopoiesis and myeloid-derived suppressor cell-differentiation in cancer.

Cancer Res 2018 Nov 2. Epub 2018 Nov 2.

Universitätsklinik und Poliklinik für Medizinische Onkologie, Inselspital

Hematopoiesis in cancer patients is characterized by reduced production of red blood cells and an increase in myelopoiesis, which contributes to the immune-suppressive environment in cancer. Some tumors produce growth factors that directly stimulate myelopoiesis such as G-CSF or GM-CSF. However, for a majority of tumors that do not directly secrete hematopoietic growth factors, the mechanisms involved in the activation of myelopoiesis are poorly characterized. Read More

View Article
November 2018
8 Reads

Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.

Carcinogenesis 2018 Oct 31. Epub 2018 Oct 31.

Institut fu¨r Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität Mu¨nchen, Munich, Germany.

Ring Finger Protein 43 (RNF43) is an E3 ubiquitin ligase that has been described to be frequently mutated in gastrointestinal cancers. RNF43 downregulation was associated with distant metastasis, TNM stage and poorer survival in patients with gastric and colorectal cancers. Functional analysis has shown that overexpressed RNF43 negatively regulates Wnt signaling by ubiquitinating Frizzled receptors and targeting them for degradation, and by sequestering T-cell factor 4 (TCF4) to the nuclear membrane, thereby inhibiting Wnt-mediated transcription. Read More

View Article
October 2018
5 Reads

[Liquid biopsy in human non-small-cell lung cancer : Blood-based analysis of ctDNA methylation].

Pathologe 2018 Oct 30. Epub 2018 Oct 30.

Arbeitsgruppe Molekulare Onkologie, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.

Background: Use of liquid biopsy for minimal invasive follow-up diagnostics of non-small-cell lung carcinomas (NSCLCs).

Objectives: Systematic search for new putative blood-based hypermethylation biomarkers to discriminate NSCLC patients from patients without a malign disease.

Methods: Quantitative analysis of gene promoter DNA methylation of potential biomarkers from cfDNA (plasma) with pyrosequencing. Read More

View Article
October 2018
1 Read

[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2018 ASCO meeting].

HNO 2018 Dec;66(12):907-912

Klinik und Poliklinik für Hals‑, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, Gebäude Ost 10, 20246, Hamburg, Deutschland.

This year, the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) was mainly dominated by immunotherapy. The corresponding studies are presented in another article. Beside this, results of phase II studies in particular were presented at the ASCO Annual Meeting, in which-as in recent years-new drugs (monoclonal antibodies, small molecules) played a major role. Read More

View Article
December 2018
1 Read

[Special situations of preconditioning and prehabilitation in oncological visceral surgery].

Chirurg 2018 Nov;89(11):903-908

Abteilung Sportmedizin, Prävention und Rehabilitation am Institut für Sportwissenschaft, Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.

Background: Prehabilitation prior to complex visceral oncological surgery is playing an increasingly important role.

Objective: The aim of this review article is to present special situations of preconditioning in visceral oncological patient cohorts. The following conditions were defined as special situations with subsequently increased risk profile: cardiopulmonary comorbidities, geriatric patients, neoadjuvant therapy and simultaneous fatigue. Read More

View Article
November 2018
7 Reads

[Adjuvant radiotherapy in the multimodal treatment of resectable gastric cancer-criticism of the conclusions drawn from CRITICS?]

Strahlenther Onkol 2018 Oct 29. Epub 2018 Oct 29.

Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland.

View Article
October 2018
4 Reads

[Positron emission tomography in germ cell tumors in men : Possibilities and limitations].

Urologe A 2018 Oct 29. Epub 2018 Oct 29.

Klinik für Onkologie, Hämatologie und Knochenmarktransplantation mit Abteilung für Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.

Background: Conventional radiographic imaging may fail to safely distinguish clinical stage I from stage IIA germ cell cancer, to localize isolated tumor marker relapses, and to equivocally identify the viability of postchemotherapy residual masses.

Objectives: To provide an overview of the diagnostic value and limitations of functional imaging by positron emission tomography with 2‑deoxy-2-[fluorine-18]fluoro-D-glucose with computed tomography (F-FDG-PET-CT) in male germ cell cancer.

Materials And Methods: A narrative review based on a literature search of PubMed/MEDLINE for original articles published from 1990-2018 and conference proceedings of ASCO (American Society of Clinical Oncology) and EAU (European Association of Urology) annual meetings 2014-2017 is presented. Read More

View Article
October 2018
5 Reads

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

J Intern Med 2018 Oct 29. Epub 2018 Oct 29.

Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.

Background: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years.

Objectives: To assess the incremental improvement of transplanted AML patients in the last two decades.

Methods: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Read More

View Article
October 2018
9 Reads

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.

Geburtshilfe Frauenheilkd 2018 Oct 19;78(10):927-948. Epub 2018 Oct 19.

Universitätsfrauenklinik Würzburg, Universität Würzburg, Würzburg, Germany.

The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure. Read More

View Article
October 2018
8 Reads

[Psychological care in the intensive care unit : Task areas, responsibilities, requirements, and infrastructure].

Med Klin Intensivmed Notfmed 2018 Oct 26. Epub 2018 Oct 26.

Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland.

The relatively high rates of mental stress among critically ill patients and their relatives implies the necessity of conceptually and financially embedded psychological care in intensive care units (ICUs). Professional associations also recommend the involvement of psychological professionals and screening of mental symptoms in critically ill patients. Intensive care medicine psychologists and psychotherapists take this as an opportunity to describe the content and goals of psychological care. Read More

View Article
October 2018
5 Reads

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Geburtshilfe Frauenheilkd 2018 Oct 19;78(10):949-971. Epub 2018 Oct 19.

Klinik für Gynäkologie und Geburtshilfe, Universitätsmedizin Göttingen, Göttingen, Germany.

The first German interdisciplinary S3-guideline on the diagnosis, therapy and follow-up of patients with endometrial cancer was published in April 2018. Funded by German Cancer Aid as part of an Oncology Guidelines Program, the lead coordinators of the guideline were the German Society of Gynecology and Obstetrics (DGGG) and the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG). The use of evidence-based, risk-adapted therapy to treat low-risk women with endometrial cancer avoids unnecessarily radical surgery and non-useful adjuvant radiotherapy and/or chemotherapy. Read More

View Article
October 2018
6 Reads

[Digital pathology in immuno-oncology-current opportunities and challenges : Overview of the analysis of immune cell infiltrates using whole slide imaging].

Pathologe 2018 Nov;39(6):539-545

Institut für Pathologie, Universitätsmedizin Mainz, Mainz, Deutschland.

Background: Immuno-oncology requires objective and standardized methods for measuring immune cell infiltrates for therapy selection and clinical trials.

Methods: Current approaches in applying digital pathology in immuno-oncology and developments in computational image analysis were analyzed.

Results: Since 2008, digital pathology has had an ever increasing importance in immuno-oncology. Read More

View Article
November 2018
4 Reads